Significant Events During the Financial Year
Progress in our clinical project portfolio is crucial for value creation for the company and our assets—this is especially true for the work with iCM012 in kidney transplantation. Earlier this year, we completed the long-term follow-up of our First-in-Human study ATMIRe (phase 1/2a) with convincing safety data and indications of efficacy. iCM012 was studied in connection with kidney transplants.

In June, we announced positive feedback from the EMA for our next planned clinical study, EMPIRe. This phase 2b study will be conducted at leading transplantation centers in Europe. There has been strong interest in participating, reflecting iCM012’s potential to improve outcomes for kidney transplant patients. Preparations are underway, and the study is expected to start in 2025.

We are also seeing great interest in our clinical and preclinical programs within the scientific community, both through publications and presentations at scientific conferences, which of course gives us additional encouragement in our continued work with iCM012. A significant milestone in 2024 was when iCoat Medical’s Chief Medical Officer was invited to present the company's clinical results at the American Society of Nephrology's conference, Kidney Week. iCoat Medical’s research also received an award from the Japanese Society for Biomaterials.

The external environment has been challenging during 2024, and as a consequence, raising capital has become more difficult. iCoat Medical has responded to this by significantly reducing its cost base.

For further information, please contact:
Peder Waern, CEO

peder.waern@icoatmedical.com